Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A review of abuse-deterrent opioids for chronic nonmalignant pain.

Literature DB >> 22876107

A review of abuse-deterrent opioids for chronic nonmalignant pain.

Robin Moorman-Li, Carol A Motycka, Lisa D Inge, Jocelyn Myrand Congdon, Susan Hobson, Brian Pokropski.

Abstract

Chronic nonmalignant pain, which affects millions of people, is the most common reason patients seek medical care. Both current and potential opioid analgesics are discussed, along with new technologies used to prevent abuse.

Entities: Disease Species

Year: 2012 PMID： 22876107 PMCID： PMC3411218

Source DB: PubMed Journal: P T ISSN： 1052-1372

18 in total

Review 1. Opioid formulations designed to resist/deter abuse.

Authors: Robert B Raffa; Joseph V Pergolizzi
Journal: Drugs Date: 2010-09-10 Impact factor: 9.546

Review 2. Opioid formulations in development designed to curtail abuse: who is the target?

Authors: Lynn R Webster; Brad Bath; Robert A Medve
Journal: Expert Opin Investig Drugs Date: 2009-03 Impact factor: 6.206

Review 3. Abuse-deterrent opioid formulations: are they a pipe dream?

Authors: Nathaniel Katz
Journal: Curr Rheumatol Rep Date: 2008-01 Impact factor: 4.592

Review 4. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Authors: Natalie J Carter; Gillian M Keating
Journal: CNS Drugs Date: 2010-04 Impact factor: 5.749

Review 5. Morphine/naltrexone.

Authors: Sean T Duggan; Lesley J Scott
Journal: CNS Drugs Date: 2010-06 Impact factor: 5.749

Review 6. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Authors: Jennifer P Schneider; Michele Matthews; Robert N Jamison
Journal: CNS Drugs Date: 2010-10 Impact factor: 5.749

Review 7. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.

Authors: Standiford Helm; Andrea M Trescot; James Colson; Nalini Sehgal; Sanford Silverman
Journal: Pain Physician Date: 2008 Mar-Apr Impact factor: 4.965

8. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors: Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal: J Pain Date: 2008-05-12 Impact factor: 5.820

Review 9. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.

Authors: Lynn R Webster
Journal: Expert Opin Investig Drugs Date: 2007-08 Impact factor: 6.206

10. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone.

Authors: Gayatri Sathyan; Emily Xu; John Thipphawong; Suneel K Gupta
Journal: BMC Clin Pharmacol Date: 2007-02-02

24 in total

1. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.

Authors: Mona Darwish; Mary Bond; William Tracewell; Philmore Robertson; Ronghua Yang
Journal: Clin Drug Investig Date: 2015-01 Impact factor: 2.859

Review 2. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors: Celeste B Burness; Gillian M Keating
Journal: Drugs Date: 2014-03 Impact factor: 9.546

Review 3. Physician Guide to Appropriate Opioid Prescribing for Noncancer Pain.

Authors: Timothy Munzing
Journal: Perm J Date: 2017

Review 4. Acute Pain Management of Chronic Pain Patients in Ambulatory Surgery Centers.

Authors: Kanishka Rajput; Nalini Vadivelu
Journal: Curr Pain Headache Rep Date: 2021-01-14

Review 5. Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.

Authors: Nalini Vadivelu; Daniel Chang; Leandro Lumermann; Thomas Suchy; Matthew M Burg; Manuel L Fontes
Journal: Curr Pain Headache Rep Date: 2017-02

6. Self-regulated Anti-Overdose Crush and Extraction-Resistant Drug Delivery System to Combat Opioid Overdose Crisis.

Authors: Patel Jayendrakumar; Patel Rakesh
Journal: AAPS PharmSciTech Date: 2022-09-26 Impact factor: 4.026

7. Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).

Authors: Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John M Corkery; Giovanni Martinotti; Daniel R Harris; Fabrizio Schifano
Journal: Pharmaceuticals (Basel) Date: 2022-05-27

Review 8. The use of opioid analgesics for chronic pain: minimizing the risk for harm.

Authors: Charles E Argoff; Eugene R Viscusi
Journal: Am J Gastroenterol Suppl Date: 2014-09-10

9. Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Authors: Célian Bertin; Jessica Delorme; Marie Riquelme; Hélène Peyrière; Georges Brousse; Alain Eschalier; Denis Ardid; Chouki Chenaf; Nicolas Authier
Journal: Br J Clin Pharmacol Date: 2019-08-24 Impact factor: 4.335

10. Design of modular dual enzyme-responsive peptides.

Authors: Natalie Boehnke; Heather D Maynard
Journal: Biopolymers Date: 2017-08-11 Impact factor: 2.240